KR101285933B1 - Acidic electrolyzed water having anti-influenza virus activity and use thereof - Google Patents

Abstract

The present invention relates to a composition having an anti-influenza virus activity including acidic ionized water and its use, wherein the composition has a prophylactic and therapeutic effect against influenza virus diseases and can be used as a pharmaceutical composition in addition to quasi-drugs and foods It can be used for various purposes.

Description

Acidic electrolyzed water having anti-influenza virus activity and its use {Acidic electrolyzed water having anti-influenza virus activity and use}

A composition having anti-influenza virus activity, including acidic ionizing water, and a use thereof.

Influenza is an infectious disease commonly called flu, or the influenza virus of the Oxomyxovirus family. Common symptoms include chills, fever, sore throat, myalgia, headache, cough, helplessness and discomfort, and mild symptoms like fever and cough are most easily seen, but can often cause fatal complications.

Influenza causes pandemic flu, which kills thousands to tens of thousands of people every season, and in the global pandemic that has occurred over the years, about one million people have died. In the 20th century, there were three global epidemics of the flu caused by new strains of influenza, killing tens of millions of people. These strains often occur when infections occur from other animals to humans, and when a species whose main host is human receives genes from a species whose main host is another animal. The emergence of H5N1, which emerged in Asia in 1997, sparked great interest in the global pandemic, but the species did not change to specialize in human-to-human infections. In April 2009, a variant of H1N1 emerged in Mexico, spreading to several countries.

Influenza is strictly divided into three of the five genus included in the RNA virus Orthomyxoviridae, influenza A, influenza B, and influenza C.

Influenza A includes only one species, the influenza A virus. Wild aquatic birds act as natural hosts for many types of influenza A. Type A can cause a major epidemic through transmission of species and is the most toxic of influenza. Type A is further divided into several serotypes (subtypes) depending on whether the antibody responds. The subtypes known to cause flu in humans are listed in descending order by number of deaths during the epidemic. First, H1N1 caused the Spanish flu epidemic of 1918 and the worldwide flu epidemic of 2009. H2N2 caused Asian flu in 1957, and H3N2 was the subtype of Hong Kong flu in 1968. In addition, subtypes of influenza A include H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, and H10N7.

Among them, H1N1 is described in more detail. Influenza virus type A H1N1 subtype (English: Influenza A virus subtype H1N1) or H1N1 is a subtype of influenza A, which is the most common type of influenza in humans. In addition to humans, pigs and birds can also be infected. It was first discovered in April 2009 as a new type of virus that contains a mixture of genetic material from human, swine, and bird flu viruses. The path of virus transmission has not yet been clearly identified, but similar to the existing seasonal influenza virus, it is mainly a person-to-person, close contact between infected and close contact with an infected person (through infection of a droplet, ie coughing or sneezing of an infected person). It is known to propagate within about 2m).

The incubation period is not clear but is estimated to be approximately 1-7 days. Symptoms include confirmed fever, chills, headache, upper airway symptoms such as cough, sore throat, runny nose and dyspnea, muscle pain, joint pain, fatigue, vomiting or diarrhea. It is usually reported to be contagious from one day before the onset of symptoms to seven days after the onset, and may be longer than 10 days in children.

Since the outbreak, the number of infected people and deaths has increased worldwide, and on June 12, 2009, the World Health Organization upgraded the pandemic warning of swine flu from phase 5 to phase 6, the highest level. This means that they have entered the "pandemic" phase of intercontinental infections. As a result, on 31 July 2009, the World Health Organization assumed that swine flu had spread worldwide and stopped reporting the number of people infected by country. As of September 4, 2009, there were 2,860 confirmed cases of deaths and 193 deaths in Mexico, the United States of America, 43,711 confirmed cases, 556 deaths, and 3,444 confirmed cases in Australia. People occurred. In Asia, Thailand was the most confirmed 16,876 patients with 130 deaths, while China had 8,406, 17 with deaths, and Japan with 5022 with 10 deaths. As of September 13, 2009, 7 deaths occurred in 7577 confirmed patients.

Influenza B, on the other hand, includes one species that is an influenza B virus. Type B is almost susceptible to humans, and is rarer than type A. Other animals suspected of having type B susceptibility are seals and ferrets. This species has two to three times lower mutation rate than type A, and there is only one subtype with low genetic diversity. Because of this low antigenic diversity, type B has a small host range and very few epidemics.

Influenza C also includes one species that is influenza C virus. Type C is susceptible to humans, dogs, and pigs, but usually only mild symptoms in children. It appears less frequently than type A and type B.

Drugs conventionally used to treat influenza include oseltamivir (trade name: Tamiflu), zanamivir (trade name: Relenza), feramivir (en: Peramivir), and amantadine (en: Amantadine). Oseltamivir, called Tamiflu, is currently used primarily for the treatment of H1N1 influenza type A. Tamiflu is the world's only monoclonal avian influenza (AI) treatment. It is an antiviral agent that has a therapeutic effect by blocking the function of the enzyme to multiply the virus, and it takes effect within 48 hours after symptoms occur. The main therapeutic effects are a reduction in the worsening of flu symptoms, a decrease in the occurrence of secondary complications such as bronchitis or pneumonia, and a decrease in the incubation period for flu. It is also used as a treatment for influenza A and B. Janamivir is also called Zanamivir and is trade name Relenza. It acts as a neuraminidase inhibitor and is used to treat influenza A and B.

However, oseltamir has a side effect of severe vomiting and zanamivir has a high antiviral effect but low bioavailability and fast discharge from the kidney. In addition, anti-influenza therapeutics developed to date have most of the side effects. Therefore, there is an urgent need for the development of new therapeutic agents that are harmless to the human body.

Meanwhile, an aqueous solution in which pH or oxidation-reduction potential (ORP) is adjusted by electrolysis is called electrolyzed water. Applying a DC voltage to the water produces ionized water that can change the pH by the movement of ions. The water produced at the anode decreases in pH due to the increase of H ⁺ ions, and the redox potential (ORP) increases, resulting in a strong oxidative state. ^­ The pH rises due to the increase of ions, resulting in a reducing state. The ionized water adjusted pH or redox potential can effectively remove impurities attached to the solid surface. In addition, it is known that there is a bactericidal effect on the ionized water as an oxidized aqueous solution.

However, no antiviral activity of ionized water, especially acidic ionized water, has been reported. Unlike bacteria, viruses cannot be separated by bacterial filters, they are so small that they can only be seen through electron microscopy, and they depend on host cells because they do not have an energy production system. In addition, viruses have only nucleic acids and a few proteins as survival materials, whereas bacteria have several organelles for producing substances necessary for survival. Viruses and bacteria have different structures. Bacteria have different physiological activities, so the mechanism of action that reacts to foreign substances is different. For example, antibiotics have antimicrobial activity, but have no antiviral activity, and this has resulted in the incidence of antibiotics in the cold, a disease caused by influenza virus (WO 1933 2006-12-11 pp. 44-48 1228-2235).

Accordingly, the present inventors have quantitatively analyzed that the acidic ionized water has antiviral activity, and found that a composition containing acidic ionized water can be usefully used for treating influenza virus disease, and completed the present invention.

It is an object of the present invention to provide a composition having anti influenza virus activity, including acidic ionized water.

Another object of the present invention to provide a pharmaceutical composition for the prevention or treatment of influenza virus diseases comprising a composition having an anti-influenza virus activity, including acidic ionized water as an active ingredient.

Still another object of the present invention is to provide a food composition for preventing or ameliorating influenza virus diseases, which comprises as an active ingredient a composition having anti-influenza virus activity including acidic ionized water.

Still another object of the present invention is to provide a quasi-drug composition for preventing or ameliorating influenza virus diseases, comprising as an active ingredient a composition having anti-influenza virus activity including acidic ionized water.

In one aspect the present invention relates to a composition having anti influenza virus activity, including acidic ionized water.

The "influenza virus" is subtyped by hemagglutinin (HA) and neuraminidase (NA), which are the surface antigens of the virus. HA plays an important role in attaching the virus to somatic cells, and there are 16 subtypes. NA plays a role in breaking the bond between existing infected cells and virus particles so that the proliferated virus can escape from infected cells and infect new somatic cells. It is divided into nine subtypes. Influenza viruses have a unique feature of antigenic mutations, large and small antigenic mutations that occur almost every year, which continue to cause epidemic influenza. There are two antigenic variants, antigenic mutants and antigenic urine, which are related to mutations in HA and NA on the surface of the influenza virus. HA is particularly important because the presence of antibodies to HA determines whether it can play a protective role in infection. Influenza viruses are divided into A-B-C types according to differences in complement binding antigens. Since influenza A virus shows various subtype changes, it is indicated as H1N1, H3N2 serotypes according to H and N types.

As used herein, the term “influenza virus” refers to all influenza viruses, including influenza virus A / H1N1, including, for example, influenza virus type B, influenza virus type C, subtypes of influenza virus type A other than influenza virus A / H1N1, And seasonal influenza virus A / H1N1. Preferably the influenza virus is influenza virus A / H1N1.

The "electrolyzed water" refers to an aqueous solution in which pH or oxidation-reduction potential (ORP) is adjusted by electrolysis. Applying a DC voltage to the water produces ionized water that can change the pH by the movement of ions. The water produced at the anode decreases in pH due to the increase of H ⁺ ions, and the redox potential (ORP) increases, resulting in a strong oxidative state. ^­ The pH rises due to the increase of ions, resulting in a reducing state.

Acidic ionized water of the present invention can be prepared using a variety of devices and known methods for electrolyzing water. The ionizer generator for generating ionized water has an electrolytic cell divided into two areas in which an anode and a cathode are disposed by a separator, and when an electric current flows through the anode, ionized reduced water is produced in the cathode part and ionized in the anode part. Acidic water is produced. Typically, a voltage of at least 2 to 3 volts or higher is supplied, a diaphragm or ion exchange membrane is installed to separate the anode and the cathode, and an electrolytic material (eg, NaCl, KCl, etc.) is added to promote electrolysis. . Many devices are commercially available for the direct electrolysis of tap water to produce acidic ionized water. The continuous generation of ionizing water is filtered by tap water using an adsorption medium such as activated charcoal, and then purified water is continuously supplied to the electrolytic cell so that the ionizing water is continuously generated. In addition, batch devices for producing ionized water comprising an anode and a cathode chamber are also well known. Apparatuses for producing acidic water suitable for various applications have been researched and developed. As a specific example, after supplying pure water to an electrolyte preparation tank, an electrolyte having a predetermined molar concentration of NH ₄ OH or HCl is prepared, and then an anode. By applying a voltage of a predetermined magnitude between the electrode and the cathode electrode, the electrolytic solution of the electrolytic chamber may be electrolyzed to produce acidic water having a desired pH from the anode.

In addition to the above-described method, a device capable of continuously generating a large amount of ionized water with high efficiency, comprising a flow restricting means in an electrolytic cell so that the raw water can maintain a long contact between the negative electrode plate and the positive electrode plate. There are known ionizing water generating apparatuses which have a very narrow interval of 0.1 mm to 3 mm.

The composition of the present invention may include an acidic ionized water produced by electrolyzing water without adding an electrolyte, an acidic ionized water produced by electrolyzing water by adding an electrolyte, or a combination thereof, wherein the electrolyte is NH _4. Cl, KCl, NaCl or a combination thereof, preferably NH ₄ Cl or NaCl.

The acidic ionized water of the present invention is an ionized water that has become an oxidative state, and has a pH of less than 7 and a redox potential (ORP) showing a positive value. The redox potential (ORP) and pH of the acidic ionized water are correlated, and as the redox potential increases to a positive value, the oxidizing power also increases.

The pH of the acidic ionized water of the present invention is not limited thereto, but may be preferably 1 to 6, more preferably 2.0 to 4.5, and even more preferably 2.2 to 4.2. In addition, the oxidation-reduction potential (ORP) of the acidic ionized water of the present invention is not limited thereto, but is preferably 400 to 1200 mV, more preferably 500 to 1200 mV, even more preferably. May be 530 to 1160 mV.

In addition, the redox potential and pH of the acidic ionized water of the present invention is not limited thereto, but preferably 500 to 1200 mV and 2.0 to 4.5, and more preferably 530 to 1160 mV and 2.2 to 4.2.

According to a specific embodiment of the present invention, the inventors have used the A / PR / 8/34 (H1N1) virus using MDCK cells, which are influenza sensitive cells, to confirm the antiviral efficacy of acidic ionizing water against influenza virus A / H1N1 virus. The growth inhibition rate of was investigated. The results showed significant antiviral efficacy of about 95% compared to distilled water, buffer, and reduced ionized water (Table 1), and when the reaction time between acidic ionized water and virus was increased from 1 minute to 5 minutes, The antiviral rate was 100%, which improved the efficacy (Table 2). Therefore, the composition containing acidic ionized water according to the present invention as an active ingredient has excellent anti-influenza virus activity as shown in Table 1 and Table 2.

In addition, as compared to the buffer (adjusted PH range to less than 7 to have acidity using distilled water) shows a significant antiviral efficacy, the acidic ionized water has a high redox potential (ORP) in order to have a significant antiviral activity It is more preferable to have In addition, when the composition of the present invention includes an acidic ionized water prepared by adding an electrolyte, the antiviral effect of the acidic ionized water added with NH ₄ Cl is superior to that of the acidic ionized water containing NaCl as an electrolyte. It is preferable to include acidic ionized water prepared by adding NH ₄ Cl as an electrolyte.

In another aspect, the present invention can be used as a pharmaceutical composition for the prevention and treatment of influenza virus disease comprising an acidic ionized water as an active ingredient, it can be treated to prevent or treat influenza virus disease.

As used herein, the term "prevention" refers to any action that inhibits or delays the onset of the disease by administration of a composition comprising an acidic ionizing water according to the present invention.

As used herein, the term "treatment" refers to any act that improves or advantageously alters the symptoms of the disease by administration of a composition comprising an acidic ionizing water according to the present invention.

Compositions comprising acidic ionized water according to the present invention can be administered to mammals such as mice, mice, livestock, humans, and the like by various routes. All modes of administration can be expected and can be administered, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.

 The throughput of the composition used in the present invention should be a pharmaceutically effective amount.

As used herein, the term “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, with an effective dose level of the subject's type and severity, age, sex, drug Activity, sensitivity to drug, time of administration, route of administration and rate of release, duration of treatment, factors including concurrent use of drugs, and other factors well known in the medical arts. Effective amounts may vary depending on the route of treatment, the use of excipients, and the possibility of use with other agents, as will be appreciated by those skilled in the art.

Compositions of the present invention may be prepared in pharmaceutical formulations using methods well known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal. In the preparation of the formulations, it is preferred that the active ingredient is mixed with or diluted with the carrier, or enclosed in a carrier in the form of a container.

Therefore, the composition of the present invention can be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral dosage forms, external preparations, suppositories, and sterile injectable solutions according to conventional methods. It may further comprise a suitable carrier, excipients and diluents commonly used in the preparation of the composition. For example, carriers, excipients and diluents which may be included in the pharmaceutical compositions of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium Phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used.

Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate, sucrose in the compound. Or lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate and the like can be used. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.

In another aspect, the composition of the present invention may be provided as a food composition for the prevention or improvement of influenza virus diseases, including acidic ionized water as an active ingredient.

The food composition of the present invention includes the form of pills, powders, granules, acupuncture, tablets, capsules or liquids, and the like to which the composition of the present invention can be added, for example, various foods, for example, Drinks, gums, teas, vitamin complexes, and dietary supplements.

There is no particular limitation on the other components other than the composition containing the acidic ionized water as an essential ingredient that may be included in the food composition of the present invention, and may include food supplement additives or natural carbohydrates, etc. as additional ingredients, like ordinary food. In addition, the food supplement may also be added to the food supplement additives include conventional food supplements, such as flavors, flavors, colorants, fillers, stabilizers and the like.

Examples of such natural carbohydrates include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (tauumatin, stevia extract (e.g., Rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. .

In addition to the above, the food composition of the present invention can be used as a flavoring agent such as a variety of nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and thickening agents (cheese, chocolate etc.), pectic acid and its salts, Salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. Others may contain pulp for the production of natural fruit juices and fruit juice drinks and vegetable drinks. These components can be used independently or in combination.

In addition, the food composition of the present invention may be in the form of any one of meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, gum, ice cream, soup, beverage, tea, drink, alcoholic beverage and vitamin complex Can be.

In another aspect, the present invention may be provided as a quasi-drug composition for the prevention or improvement of influenza virus diseases comprising a composition containing an acidic ionized water as an active ingredient.

That is, the composition of the present invention may be added to the quasi-drug composition for the purpose of preventing or ameliorating influenza virus diseases. In particular, the quasi-drug composition of the present invention can be usefully applied to the prevention / control operations of foot and mouth by spraying by a pest control machine, sprinkler, vehicle sterilizer, foot-and-mouth sterilizer, interpersonal sterilizer and the like.

When the composition of the present invention is used as an quasi-drug additive, acidic ionized water may be added as it is, or may be used together with other quasi-drugs or quasi-drug components, and may be appropriately used according to a conventional method. The mixed amount of the active ingredient may be suitably determined depending on the purpose of use (control, prevention, disinfection, prevention, health or therapeutic treatment).

Preferably, the composition is to be used in the preparation of antiseptic cleaners, shower foams, gagrins, wet wipes, detergent soaps, hand washes, humidifier fillers, masks, ointments, coating agents, filter fillers, protective agents, antifouling sprays, disinfectants, antiviral sprays. Can be.

The composition having an anti-influenza virus activity including the acidic ionizing water of the present invention may be used as a pharmaceutical composition having a prophylactic and therapeutic effect against influenza virus diseases, and may be applied to various fields such as quasi-drugs and foods. . In addition, the acidic ionized water is a natural ingredient, not an artificially synthesized material, and is safe and has no toxic or side effects, and thus, the composition including the acidic ionized water has an advantage that it can be taken for a long time.

Hereinafter, the present invention will be described in more detail by way of examples. However, the following examples are illustrative of the present invention, and the contents of the present invention are not limited by the following examples.

Example 1 Preparation of Acidic Ionized Water

Ultra pure water or filtered tap water, the third distilled water prepared through distillation and reverse osmosis, in a solid NaCl in an amount of 0.002%, 0.008%, 0.02%, or NH in an amount of 0.01%, 0.02%, 0.04% _An acidic ionized water was prepared by adding ₄ Cl solution (480 mL of NH ₄ OH; 120 mL HCl; 900 mL distilled water), followed by electrolysis.

As a result, the pH of the acidic ionized water prepared by adding 0.002% NaCl was 4.2 and the ORP was 789 mV, the pH of the acidic ionized water prepared by adding 0.008% NaCl was 3.5 and the ORP was 996 mV, 0.02 The acidic ionized water prepared by adding% NaCl had a pH of 2.2 and an ORP of 1158 mV. In addition, the pH of the acidic ionized water prepared by adding 0.01% NH ₄ Cl solution was 4.2 and the ORP was 700 mV or 538 mV, and the pH of the acidic ionized water prepared by adding 0.02% NH ₄ Cl solution was 3.5 The ORP was 1039 mV, and the pH of the acidic ionized water prepared by adding 0.04% NH ₄ Cl solution was 2.2 and the ORP was 1104 mV.

Example  2. Experimental Method

1. Cell and virus lines

 1) host cell

Madin-Darby canine kidney (MDCK) passage cell line, an influenza sensitive cell, was proliferated and used. The cell culture medium contained 10% bovine serum (Fetal bovine serum, FBS, HyClone) in the minimum essential medium (MEM, HyClone).

2) virus strain

The virus used in the experiment was A / PR / 8/34 (H1N1). Viruses were incubated with embryonated hen's eggs at 37 ° C. incubation for 10 days and then inoculated with 0.1 ml of the virus to chorioallantoic sac for 3 days at 37 ° C. After leaving the fertilized egg overnight at 4 ℃, the urine solution was recovered. After passing the virus-containing urine solution through a 0.2 μm filter, the titer of the virus was measured by a hemagglutination assay, and then dispensed in 1 ml and stored in an ultra-cold freezer at -80 ° C. It was melted again and used for the test.

2. Determination of the titer of virus

 1) Hemagglutination

A hemagglutination assay (HA) was performed to measure the titer of virus propagated in the urinary fluid of SPF fertilized eggs. The measurement method of HA was performed by diluting virus samples in a microtitration plate two times and administering 50 µl each, and then adding 50 µl of 0.5% chicken RBC solution washed with PBS to cause aggregation with the virus. After reacting at room temperature for 60 minutes, the aggregation titer was measured in comparison with the negative control group.

 2) plaque assay

Plaque assay was performed to measure the titer of viable viable virus. The reaction samples were serially diluted 10-fold using MEM medium to identify the viable virus present in the sample. Diluted samples were inoculated with 200 [mu] l of each well of a 12 well plate to give infection time at room temperature for 1 hour. After removing the infection solution, the medium was mixed with 2x MEM and 2% low melting agarose in half and poured. After confirming that the solution was solid at room temperature, the culture solution was incubated in a 37 ° C CO ₂ incubator for 2-3 days. After the incubation, 4% formaldehyde (sol) sol was added to each well by 1 ml and fixed. After fixation the overlay media was removed and stained with 0.1% crystal violet solution to count the flocs.

Example 3. Experimental Results

As shown in Table 1 (Antiviral efficacy when acidic ionized water and H1N1 virus were reacted for 1 minute), when the virus was reacted with acidic ionized water at pH 4.2 for 1 minute, the antiviral efficacy was 92.4% compared to distilled water. . In comparison, the same pH of 5 mM Sodium acetate buffer showed only about 7.5% antiviral efficacy. In addition, the reduced ionized water at pH 11 showed only 33% antiviral efficacy.

Sample name pH ORP
(mA) Virus titer pfu / ml Antiviral Rate (%)
Reaction time Distilled water 6.5 390 4,025,000 0 1 minute Acidic ionized water
(NH ₄ Cl) 4.2 700 307,500 92.4 1 minute buffer 4.2 447 3,725,000 7.5 1 minute Reduction ionization 11 -805 3,100,000 33 1 minute

In addition, Table 2 (Antiviral efficacy when the acidic ionized water and H1N1 virus was reacted for 5 minutes) shows that when the reaction time between the sample and the virus was increased to 5 minutes, NH ₄ Cl was added as an electrolyte. Acidic ionized water (pH 3.5; ORP 1039 mV) showed good antiviral efficacy of 98.6%. In comparison, 5 mM sodium acetate buffer (pH 3.5; ORP 424 mV) at the same pH showed only 8.1% antiviral efficacy.

In addition, as shown in Table 2, the antiviral rate of the acidic ionized water at pH 2.2 was 100%, which showed the effect of completely killing the virus. This result was effective in killing the influenza virus separately from ORP at low pH. To indicate. This effect indicates that it can be effectively used for quarantine and the like by using environmentally-produced acidic ionized water without using chemicals.

In addition, the antiviral effect of acidic ionized water showed that the antiviral effect of acidic ionized water added with NH ₄ Cl as an electrolyte at the same pH was superior to that of NaCl added acidic ionized water. In case of, the higher the ORP, the better the antiviral effect. These results indicate that the antiviral effect of acidic ionized water with low pH and high positive ORP is positive. For acidic ionized water prepared by adding electrolyte, NH ₄ Cl is used as electrolyte. Good antiviral effect.

Sample name Electrolyte Type pH ORP
(mA) Virus titer pfu / ml Antiviral Rate (%)
Reaction time Distilled water - 6.5 390 3,400,000 0 5 minutes Acidic ionized water NH ₄ Cl 4.2 700 97,500 97.1 5 minutes Acidic ionized water NH ₄ Cl 4.2 538 1,173,000 65.5 5 minutes Acidic ionized water NaCl 4.2 789 2,002,600 41.1 5 minutes Acidic ionized water NH ₄ Cl 3.5 1039 47,600 98.6 5 minutes Acidic ionized water NaCl 3.5 996 1,594,600 53.1 5 minutes Acidic ionized water NH ₄ Cl 2.2 1104 0 100 5 minutes Acidic ionized water NaCl 2.2 1158 0 100 5 minutes buffer - 4.2 447 3,350,000 1.5 5 minutes buffer - 3.5 424 3,125,533 8.1 5 minutes Reduction ionization NH ₄ Cl 11 -805 2,675,000 21.3 5 minutes

Claims (10)

A composition prepared using NH ₄ Cl as an electrolyte, and having an anti-influenza virus activity including an acidic ionizing water having an oxidation-reduction potential (ORP) of 700 to 1200 mV and a pH of 2.0 to 4.5.
The composition of claim 1, wherein the influenza virus is influenza A virus, influenza B virus, or influenza C virus.
The composition of claim 2, wherein the influenza A virus is H1N1 influenza virus.
The composition of claim 3, wherein the H1N1 influenza virus is A / PR / 8/34 (H1N1).
The composition of claim 1, wherein the acidic ionized water has a pH of 2.2.
delete delete A pharmaceutical composition for preventing or treating influenza virus diseases comprising the composition of any one of claims 1 to 5 as an active ingredient.
Food composition for the prevention or improvement of influenza virus diseases comprising the composition of any one of claims 1 to 5 as an active ingredient.
A quasi-drug composition for prevention or improvement of influenza virus diseases comprising the composition of any one of claims 1 to 5 as an active ingredient.